Brett R Hagen
CIK 1681782 · Chief Accounting Officer · last filed 2026-03-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALVR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | Chief Accounting Officer | 0 | $2.34 | $0 | -$21.0K | 3 | 2026-03-23 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Chief Accounting Officer | 2,832 | $9.81 | $27.8K | -$707.1K | 44 | 2025-02-24 |
| KINETA, INC./DE (PTI) Delisted | See Remarks | — | — | — | $0 | 2 | 2017-04-05 |
Recent Filings · Page 8 of 9
84 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-10-24 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −13,679 | -$115.3K | EDGAR |
| 2022-08-17 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2022-07-06 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +10,500 | $0 | EDGAR |
| 2022-04-22 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −276 | -$1.8K | EDGAR |
| 2022-04-04 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +17,442 | $0 | EDGAR |
| 2022-01-24 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −1,563 | -$13.7K | EDGAR |
| 2021-02-23 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −800 | -$34.5K | EDGAR |
| 2021-02-19 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −741 | -$29.7K | EDGAR |
| 2021-02-18 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −5,370 | -$221.6K | EDGAR |
| 2021-01-21 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +17,500 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.